The NCH Rooney Heart Institute, part of Naples (Fla.) Comprehensive Health, said it became the first hospital in the U.S. to adopt both of Caristo Diagnostics’ AI tools for early heart disease detection.
The institute is deploying CaRi-Plaque, an FDA-approved technology that analyzes coronary CT angiography scans to detect high-risk plaque. It will also pilot CaRi-Heart, which quantifies coronary inflammation — a predictor of heart attack up to 10 years before symptoms appear — as part of a research program, according to a Nov. 5 news release.
CaRi-Heart is widely used in Europe and currently under FDA review. Patients who qualify for plaque analysis will automatically have their scans analyzed with CaRi-Plaque, while CaRi-Heart will provide additional inflammation-based risk scores to support preventive care planning.
NCH is also launching a self-pay program for asymptomatic patients interested in proactively managing their heart health using the new AI-based technologies.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.